For someone who has lost the ability to move after a spinal cord injury, the possibility of standing again, let alone walking, can seem beyond reach.
In Japan, four men with severe spinal cord injuries received an experimental treatment involving stem cell-derived neural progenitor cells. A year later, one man’s injury had improved from the most severe grade to a much milder one, and his motor scores had roughly doubled. Another had recovered some voluntary movement. The remaining two showed smaller neurological improvements.
No graft-related tumours were detected during follow-up lasting up to four years. The findings, published in Nature Medicine in July 2026, have understandably generated excitement. But four patients, however encouraging their progress, do not establish a new treatment.
Have researchers finally found a way to repair the damaged spinal cord, or are we witnessing the early promise of a treatment that still has much to prove?
AI-generated illustrationContents
- Why is spinal cord injury so difficult to repair?
- Four patients, two million cells each
- Where did the stem cells come from?
- Did the treatment really work?
- What about safety?
- What does the combined evidence tell us?
- What about patients paralysed for years?
- Beyond stem cells — other ways to restore movement
- What should patients make of these findings?
- At the kerbside
- Sources & further reading
Why is spinal cord injury so difficult to repair?
The spinal cord is the main communication highway between the brain and the rest of the body. Nerve fibres carry instructions for movement and information about sensation. When the spinal cord is injured, some of these pathways are damaged or destroyed. Swelling, inflammation and loss of blood supply can cause further damage.
Unlike many tissues, the adult spinal cord has very limited ability to regenerate damaged pathways. Scar formation and changes around the injury create additional barriers. The consequences depend on the level and severity of injury. Damage in the neck may affect both arms and legs; bladder, bowel and autonomic functions may also be affected.
Modern surgery, specialist care and rehabilitation have improved outcomes. But restoring nerve connections that have been lost remains one of medicine’s greatest challenges.
Four patients, two million cells each
Researchers at Keio University conducted a Phase 1 study involving four Japanese men aged 26 to 66 with severe traumatic cervical spinal cord injuries. All four were classified as AIS A on the American Spinal Injury Association Impairment Scale, indicating neurologically complete injuries. The small, all-male Japanese group also limits how widely the findings can be generalised.[1]
ⓘ What is the AIS scale? — Click to expand
The American Spinal Injury Association Impairment Scale (AIS) describes neurological impairment after spinal cord injury. It is based on a standardised examination of sensation and muscle strength, including the lowest sacral segments.
| Grade | Meaning |
|---|---|
| A | Complete: no sensory or motor function is preserved in sacral segments S4–S5. |
| B | Sensory incomplete: sensation is preserved below the neurological level, including sacral segments, but criteria for motor incomplete injury are not met. |
| C | Motor incomplete: more than half of key muscles below the neurological level have strength below grade 3. |
| D | Motor incomplete: at least half of key muscles below the neurological level have strength of grade 3 or more. |
| E | Normal sensory and motor examination in a person with a previous spinal cord injury-related neurological deficit. |
Grade 3 muscle strength means movement against gravity. AIS A does not necessarily mean there is no movement anywhere below the neck; AIS D does not automatically mean independent walking.
Between 15 and 27 days after injury, each patient received approximately two million induced pluripotent stem cell (iPSC)-derived neural stem/progenitor cells, injected directly into the injured spinal cord. They had previously undergone spinal stabilisation and also received temporary immunosuppression and rehabilitation.
At one year, one patient improved from AIS A to AIS D. Another improved to AIS C, regaining some voluntary movement. The other two remained AIS A, although their motor scores improved. Even limited arm and hand function may make a meaningful difference to daily independence.[1]
Selected references: 1.
Where did the stem cells come from?
iPSCs are created by reprogramming mature cells into a state from which they can develop into different cell types. In this study, the cells came from a healthy donor, not from the patients themselves. They were made from donated cord blood and carry a tissue type that is common in Japan. How closely each patient matched the donor varied from none to full, and the authors saw no clear link between matching and recovery. Researchers directed the cells to become neural stem/progenitor cells capable of developing into specialised nervous-system cells.[1]
The hope is that these cells might support surviving neurons, replace damaged cells, help restore myelin around nerve fibres or encourage new connections. Animal experiments support several possible mechanisms. The human study, however, could not demonstrate whether transplanted cells survived long-term, integrated into functional circuits or caused the observed recovery.[1], [3]
The fundamentals of pluripotent stem cells were discussed in my earlier Kerbside Consult article, The Cell That Could Become Almost Anything.
Did the treatment really work?
This is where an encouraging observation must be distinguished from proof. Phase 1 trials primarily investigate safety and feasibility. This was not a randomised controlled trial designed to establish treatment efficacy.
Two of the four patients improved from AIS A to AIS C or D. The 66-year-old who reached AIS D saw his total motor score, a measure of muscle strength out of 100, rise from 38 to 78. The leg part of that score, out of 50, went from 8 to 39. These are substantial neurological gains, but the published study does not show that he regained independent walking.[1]
For context, the authors compared the four patients with a historical group of Japanese patients with similar injuries. Over the first year, the transplanted patients gained a median of 13 motor-score points, with individual gains ranging from 10 to 40. The historical patients gained 7 points, or 4 points when the authors filled in missing results using each patient’s last recorded score. Two of the four patients (50%) reached AIS C or better, compared with 12% to 15% of the historical patients, depending on the method. This was not a randomised comparison, and differences in baseline characteristics or care could influence the result.[1]
Some recovery can occur naturally after recent spinal cord injury. The investigators themselves cautioned that the observed changes could not be attributed to the intervention. Without randomisation, we cannot separate any effect of the transplanted cells from spontaneous recovery, surgery and rehabilitation.[1]
Selected references: 1.
What about safety?
Stem cell-derived treatments carry concerns about unwanted tissue growth, tumours and immune responses. Injection into the spinal cord is delicate surgery; immunosuppression also introduces risks. Across the earlier controlled studies, fever was reported more frequently in cell-treated patients; this is another reason not to describe cell therapy as uniformly safe.[5]
No graft-related tumours were detected during two to four years of follow-up. The study nevertheless recorded procedural and treatment-related complications. Low magnesium levels and urinary tract infections were reported in all four patients; cerebrospinal fluid leakage was among the surgical adverse events. One serious adverse event was recorded: a single high potassium blood result, considered probably a sampling artefact. These distinctions matter: absence of graft-related tumours in four people does not establish long-term safety.[1]
What does the combined evidence tell us?
The Japanese study is not an isolated report of neurological improvement. Researchers in several countries have investigated different cell-based treatments for spinal cord injury, including mesenchymal stem cells, neural progenitors and cells intended to support or restore myelin. The treatments, however, are not interchangeable.
A 2021 meta-analysis by Tang and colleagues included nine controlled studies involving 328 patients. Compared with control groups, cell transplantation was associated with greater odds of improvement by at least one AIS grade (odds ratio 6.06; 95% confidence interval 3.16–11.62). This is an encouraging signal, although some studies were not randomised, blinding was limited and the overall risk of bias was assessed as moderate.[5]
A 2025 review by Troiani and colleagues examined 30 human studies involving 656 patients. It reported AIS grade improvement in 43.3%, motor improvement in 49.4% and sensory improvement in 73.6%. But these percentages describe changes observed after treatment, not the proportion of recoveries proved to have been caused by it. Most studies had no comparison group, and none of the included studies used iPSCs of the type transplanted in Japan.[6]
iPSC-based products are only now being tested. A recent review lists XS228, an iPSC-derived product in a Phase 1 randomised trial in China for recent (subacute) injury (NCT06976229), but no results are available yet.[3]
A 2026 meta-analysis, available only as a conference poster abstract rather than a full research paper, pooled 14 randomised trials and reported a mean motor-score advantage of 4.76 points (95% confidence interval 3.05–6.46). However, some of the reported statistics appear inconsistent with one another, and results varied widely between trials, particularly for sensation. Until the complete methods and data can be scrutinised, this finding deserves less weight than a fully published trial report.[7]
These reviews overlap in the trials they include. Their patient totals must not be added together as though they represented separate populations. An improvement in an AIS grade or motor score also does not necessarily mean that someone can stand, walk or live independently.
Taken together, the studies offer encouraging signals of neurological improvement, including from controlled comparisons[5], [7]. Yet cell preparations, study methods and patient populations differ, while functional outcomes have been heterogeneous and generally modest[2], [3]. Clinically meaningful, lasting recovery beyond standard care remains unproven.
What about patients paralysed for years?
This is likely to be the first question asked by many patients and families. The Japanese patients were treated within approximately four weeks of injury. Someone living with paralysis for five, ten or twenty years faces a different biological problem, including scar tissue, cavities and longstanding changes to neural pathways.
The 2025 review by Troiani and colleagues is relevant here. Its patients had, on average, been injured for about four years, and most of those with recorded grades (71%) were AIS A. About 10% of patients in the comparison groups of four of the studies also improved, against 43% of treated patients. That gap is encouraging, but those comparisons were not randomised, and they remind us that some change can occur without treatment. These studies involved varied cell therapies, not the Japanese iPSC product.[6]
At the International Society for Stem Cell Research meeting in July 2026, Keio researchers presented preclinical findings involving gliogenic neural stem/progenitor cells, designed to generate support cells including astrocytes and oligodendrocytes. Oligodendrocytes make myelin—the insulation around nerve fibres.[4]
Rather than growing entirely new pathways, this approach aims to improve signalling in surviving but poorly functioning nerve fibres. The group announced plans for a clinical trial targeting recruitment in 2027 for chronic incomplete spinal cord injury. The findings presented were preclinical; they were not evidence of restored movement in patients with longstanding complete paralysis.[4]
Beyond stem cells — other ways to restore movement
While researchers are exploring ways to repair the spinal cord with stem cells, other approaches attempt to help patients regain movement without necessarily repairing the damaged tissue.
Robotic exoskeletons are wearable powered frames that support the body and help selected patients stand or practise walking. They are used in specialised rehabilitation, generally with supervision or walking aids. They assist movement rather than reconnect damaged nerves.[11]
Brain–computer interfaces interpret signals associated with intended movement. Neuralink has enabled participants with severe paralysis to control computers; in December 2025, news coverage of company demonstrations reported that participants could also control external robotic arms. This remains experimental and is not the same as restoring movement in a patient’s own limbs.[8], [12]
In 2023, Swiss researchers described a man with longstanding incomplete cervical spinal cord injury who could stand and walk using a digital bridge between brain recordings and electrical stimulation of spinal circuits. He also improved his ability to walk with crutches when the system was switched off. This was a single-patient study.[9]
In 2026, a different experimental neuroprosthesis enabled a man with severe tetraplegia to control movements of his own hand and regain useful activities, including self-feeding. Some gains in elbow strength and tactile sensation persisted after stimulation was stopped. Again, this was evidence from one participant.[10]
These approaches are not interchangeable with stem cell transplantation. One seeks biological repair; others assist movement, bypass interrupted pathways or activate surviving circuits. The future may involve combinations of regenerative medicine, neurostimulation, robotic assistance and rehabilitation, but whether these combinations produce greater and lasting recovery remains to be established.
What should patients make of these findings?
Stem cell interventions are commercially promoted for many conditions, often ahead of convincing evidence. Patients and families should distinguish a registered clinical trial from a treatment sold on the strength of animal experiments or a few encouraging cases.
Anyone considering such treatment should ask whether it is part of a properly registered and ethically approved trial, what outcomes have been independently documented, and what risks and costs are involved. Established rehabilitation and specialist care remain essential.
At the kerbside
For someone who has lost the ability to move, standing again may represent an extraordinary achievement. The four Japanese patients remind us why regenerative medicine matters. Even small improvements in movement may transform independence and daily life.
The Japanese trial did not establish that transplanted cells caused recovery. Other clinical studies offer encouraging signals, but we still lack a treatment that can reliably restore walking or independence.
Biological repair, electronic interfaces and rehabilitation may eventually complement one another. Whether combining them produces more lasting recovery remains to be tested.
The next step is larger, rigorously controlled trials that compare specific cell products with standard care, distinguish treatment effects from natural recovery, and measure meaningful long-term function as well as safety.
The spinal cord may not be entirely beyond repair. But restoring its lost function reliably remains a goal, not yet an achievement.